Score Overview
Explore the 2021 public Archive ranking →
Where Corcept Therapeutics Incorporated has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- CORT
2009: 89.9% · 2021: 21.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 114.74 | — |
1 Year2025-09-29 | $ 83.90 | 36.76% |
5 Years2021-09-29 | $ 19.93 | 475.72% |
10 Years2016-09-29 | $ 6.30 | 18x |
20 Years2006-09-29 | $ 0.93 | 123x |
All Time2004-04-14 | $ 12.23 | 9x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2004-04-14 |
|---|---|---|---|---|---|---|
| Price | $ 114.74 | $ 83.90 | $ 19.93 | $ 6.30 | $ 0.93 | $ 12.23 |
| Return | — | 36.76% | 475.72% | 18x | 123x | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 830M | $ 54M | $ 308M |
| 2025 | $ 761M | $ 99M | $ 372M |
| 2024 | $ 675M | $ 139M | $ 383M |
| 2023 | $ 482M | $ 106M | $ 368M |
| 2022 | $ 401M | $ 101M | $ 431M |
| 2021 | $ 365M | $ 112M | $ 223M |
| 2020 | $ 353M | $ 106M | $ 476M |
| 2019 | $ 306M | $ 94M | $ 275M |
| 2018 | $ 251M | $ 75M | $ 206M |
| 2017 | $ 159M | $ 129M | $ 104M |
| 2016 | $ 81M | $ 8M | $ 51M |
| 2015 | $ 50M | -$ 6M | $ 40M |
| 2014 | $ 26M | -$ 31M | $ 24M |
| 2013 | $ 10M | -$ 46M | $ 54M |
| 2012 | $ 3M | -$ 38M | $ 93M |
| 2011 | $ 0.00 | -$ 32M | $ 39M |
| 2010 | -$ 25M | $ 24M | |
| 2009 | $ 29K | -$ 20M | $ 23M |
| 2008 | $ 209K | -$ 20M | $ 18M |
| 2007 | $ 482K | -$ 11M | $ 17M |
| 2006 | $ 294K | -$ 24M | $ 9M |
| 2005 | -$ 20M | $ 29M | |
| IPO2004 | -$ 15M | $ 37M |
Corcept Therapeutics Incorporated fundamental performance
Between 2020 and 2025, revenue grew from $ 353M to $ 761M and net income declined from $ 106M to $ 99M. Revenue increased in every one of those 5 years; net income in 2.
Between 2015 and 2025, revenue grew from $ 50M to $ 761M and net income went from -$ 6M to $ 99M. Revenue increased in every one of those 10 years; net income in 6.
Corcept Therapeutics Incorporated currently holds a 20-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.
Membership
Continue CORT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
